High-resolution genomic and expression analyses of copy number alterations in breast tumors.

MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25

Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13

The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res (2010) 3.37

Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol (2011) 2.64

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07

Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One (2009) 2.04

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01

Regulation and function of miRNA-21 in health and disease. RNA Biol (2011) 1.99

Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One (2010) 1.85

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res (2010) 1.62

Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One (2010) 1.60

Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One (2012) 1.57

Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One (2010) 1.54

Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene (2009) 1.51

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics (2010) 1.50

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol (2013) 1.46

Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol (2010) 1.43

Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38

Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev (2011) 1.36

p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol (2009) 1.36

High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics (2009) 1.33

The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (2010) 1.28

Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res (2010) 1.23

Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One (2013) 1.07

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest (2012) 1.06

Inferring causal genomic alterations in breast cancer using gene expression data. BMC Syst Biol (2011) 1.06

Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One (2012) 1.01

Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast. BMC Cancer (2010) 1.00

A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc Natl Acad Sci U S A (2011) 0.99

Genome-wide identification of somatic aberrations from paired normal-tumor samples. PLoS One (2014) 0.98

Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol (2013) 0.97

Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review. Brief Bioinform (2012) 0.96

Copy number abnormalities in sporadic canine colorectal cancers. Genome Res (2010) 0.95

Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. Radiat Oncol (2013) 0.95

Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur J Hum Genet (2010) 0.92

ACNE: a summarization method to estimate allele-specific copy numbers for Affymetrix SNP arrays. Bioinformatics (2010) 0.91

Anti-apoptotic effect of microRNA-21 after contusion spinal cord injury in rats. J Neurotrauma (2013) 0.91

Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study. BMC Cancer (2010) 0.90

NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle (2011) 0.89

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. Cancer Med (2013) 0.88

Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes. World J Gastroenterol (2011) 0.88

Concurrent gene signatures for han chinese breast cancers. PLoS One (2013) 0.88

microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res (2014) 0.87

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res (2011) 0.87

Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86

Major chromosomal breakpoint intervals in breast cancer co-localize with differentially methylated regions. Front Oncol (2012) 0.84

ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. PLoS One (2013) 0.84

ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. BMC Cancer (2012) 0.83

Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. PLoS One (2010) 0.83

Astrocytes derived from trisomic human embryonic stem cells express markers of astrocytic cancer cells and premalignant stem-like progenitors. BMC Med Genomics (2010) 0.82

The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol (2013) 0.82

USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome (2010) 0.81

Modify or die?--RNA modification defects in metazoans. RNA Biol (2014) 0.80

Genome-wide Mapping of Copy Number Variations Using SNP Arrays. Transfus Med Hemother (2009) 0.78

Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. Sci Rep (2016) 0.78

The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity. BMC Cancer (2015) 0.77

Genome-wide integrative analysis revealed a correlation between lengths of copy number segments and corresponding gene expression profile. Bioinformation (2011) 0.77

Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. PLoS One (2013) 0.77

Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering. BMC Genomics (2010) 0.77

Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomark Cancer (2016) 0.75

ZNF703 Overexpression may act as an oncogene in non-small cell lung cancer. Cancer Med (2016) 0.75

Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins. Mod Pathol (2013) 0.75

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget (2016) 0.75

CNARA: reliability assessment for genomic copy number profiles. BMC Genomics (2016) 0.75

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

The diploid genome sequence of an Asian individual. Nature (2008) 46.29

Integrative genomics viewer. Nat Biotechnol (2011) 42.83

A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05

Genetics of gene expression surveyed in maize, mouse and man. Nature (2003) 22.17

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66

International network of cancer genome projects. Nature (2010) 20.35

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05

The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

A landscape of driver mutations in melanoma. Cell (2012) 12.61

High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15

The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60

Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92

A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23

The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13

Outcome signature genes in breast cancer: is there a unique set? Bioinformatics (2004) 7.96

An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61

ZDOCK: an initial-stage protein-docking algorithm. Proteins (2003) 7.52

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14

Gene discovery and annotation using LCM-454 transcriptome sequencing. Genome Res (2006) 7.10

Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93

A highly annotated whole-genome sequence of a Korean individual. Nature (2009) 6.91

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89

A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet (2003) 6.82

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine (2009) 6.30

PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res (2003) 6.19

Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev (2010) 6.05

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95

SNP discovery via 454 transcriptome sequencing. Plant J (2007) 5.92

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68

MicroRNA-mediated conversion of human fibroblasts to neurons. Nature (2011) 5.59

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38

The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23